Steven Pieper Sells 27,600 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 27,600 shares of Xeris Biopharma stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00. Following the completion of the transaction, the insider directly owned 1,366,053 shares in the company, valued at approximately $11,638,771.56. The trade was a 1.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Trading Up 6.8%

XERS traded up $0.57 during trading on Tuesday, hitting $8.94. 3,479,668 shares of the stock traded hands, compared to its average volume of 1,914,952. The firm has a market capitalization of $1.54 billion, a P/E ratio of 149.00 and a beta of 0.62. Xeris Biopharma Holdings, Inc. has a 12-month low of $4.66 and a 12-month high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The firm has a 50-day moving average of $6.65 and a 200 day moving average of $6.64.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $83.13 million for the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. Equities research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Xeris Biopharma presently has an average rating of “Hold” and an average price target of $10.80.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Cetera Investment Advisers lifted its position in shares of Xeris Biopharma by 3.9% in the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after purchasing an additional 1,735 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after buying an additional 1,820 shares in the last quarter. Royal Bank of Canada raised its stake in Xeris Biopharma by 6.5% in the fourth quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock worth $304,000 after buying an additional 2,351 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in Xeris Biopharma by 17.7% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,070 shares of the company’s stock worth $126,000 after buying an additional 2,420 shares during the period. Finally, AlphaCentric Advisors LLC lifted its holdings in Xeris Biopharma by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock worth $266,000 after buying an additional 2,494 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.